Today's 3 Worst Stocks in the S&P 500

Lorillard, Best Buy, and Regeneron Pharmaceuticals all end as significant decliners in the stock market today

Feb 12, 2014 at 7:12PM

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

The stock market cooled off today, as both the S&P 500 Index and the Dow Jones Industrial Average broke four-day win streaks in the face of another massive winter storm. The wintery weather -- which has already committed the ultimate sin in the sporting world by forcing the postponement of the UNC-Duke college basketball showdown tonight -- poses a threat to traffic, commerce, and power lines on the East Coast. Still, Wall Street wasn't that intimidated, and the S&P lost just 0.5 points, or less than 0.1%, to end at 1,819 today. 

Despite only a modest downturn in the market today, shares of tobacco giant Lorillard (NYSE:LO) slumped 5% Wednesday, as fourth quarter earnings came in below estimates. While sales and net margins both rose in the period, the increases weren't quite what Wall Street expected. Lorillard only managed to boost revenue by 1.4% last quarter, and had to fight lower cigarette volumes with higher prices in order to do so. With the incredible amount of regulatory scrutiny facing this industry, this may be a trend investors have to get used to, as smoking in public becomes more stigmatized and retailers like CVS decide to consciously shun tobacco products. 

Big-box electronics retailer Best Buy (NYSE:BBY) also ended as one of the worst performers in the S&P, falling 2.1% Wednesday despite the lack of a significant catalyst. Best Buy shares right now are extremely susceptible to changing emotions in the market -- more so than the average stock -- because of its significant underperformance so far in 2014. It's down more than 37% this year, as Wall Street hasn't yet been able to forgive Best Buy for its abysmal same-store sales numbers over the holiday period, when the metric fell by 0.9%. While this may be an instance of emotions running wild and bearishness irrationally overpowering the upside case, the sales trend is indeed troubling and I'll be looking for sustainable revenue growth before adding this stock to my portfolio. 

Lastly, shares of $31 billion biotech Regeneron Pharmaceuticals (NASDAQ:REGN) lost 1.9% today, as today's profit-taking mood sent shares lower. Profit-taking was precisely the culprit in today's slight downturn, since the last major news to come out of the company was yesterday's blowout earnings report. Shares of Regeneron Pharmaceuticals, which have rocketed more than 750% in the past three years alone, have launched atmospherically higher primarily on the strong performance of its macular degeneration drug, Eylea. Total revenue surged 47% in the most recent quarter, and the blockbuster drug is expected to continue selling well in the coming year, as Regeneron forecast Eylea sales to come in between $1.7 billion and $1.8 billion, a marked increase from its $1.41 billion showing last year.

2 game-changing biotechs revolutionizing the way we treat cancer
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

John Divine has no position in any stocks mentioned. You can follow him on Twitter, @divinebizkid, and on Motley Fool CAPS, @TMFDivine.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers